TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Open-labelled, Randomised, Two-group Parallel Trial Comparing the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After 26 Weeks of Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily, Both With Insulin Aspart at Mealtimes
Brief Summary: This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH (Neutral Protamine Hagedorn) (both combined with insulin aspart at the main meals) in overweight and obese subjects with type 2 diabetes.


Options:
A: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir | Arm Label: insulin NPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin NPH | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): insulin NPH
B: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A
C: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin
D: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Clinical Study With Early Treatment Intensification In Patients With High- Risk Hodgkin Lymphoma, Identified As FDG-PET Scan Positive After 2 Conventional ABVD Courses
Brief Summary: The purpose of this multicenter clinical trial is to assess the clinical impact of dose intensification performed very early during treatment in a subset of poor prognosis, advanced-stage Hodgkin Lymphoma patients, defined as PET-positive after two courses of conventional adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPP escalated | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: BEACOPP escalated | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPP escalated | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): B | Intervention Type: DRUG; Name: BEACOPP escalated; Assigned to Arm(s): A, B, C, D
B: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Involved Field Radiotherapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Other: No further treatment | Intervention Type: RADIATION; Name: Involved Field Radiotherapy; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: No further treatment; Assigned to Arm(s): Arm II
C: Arm Label: PET pos; Type: EXPERIMENTAL; Interventions: Drug: ESCALATED BEACOPP | Arm Label: PET negative; Type: OTHER; Interventions: Drug: CONVENTIONAL ABVD | Intervention Type: DRUG; Name: ESCALATED BEACOPP; Assigned to Arm(s): PET pos | Intervention Type: DRUG; Name: CONVENTIONAL ABVD; Assigned to Arm(s): PET negative
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Intervention Type: DRUG; Name: Adriamycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: DTIC; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: RADIATION; Name: 30 Gy IF-RT; Assigned to Arm(s): Arm A, Arm C | Intervention Type: RADIATION; Name: 20 Gy IF-RT; Assigned to Arm(s): Arm B, Arm D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High and Low Carbohydrate Weight Loss Approaches to Type 2 Diabetes Mellitus (The Diabetes Dietary Study (DDS))
Brief Summary: The purpose of this study is to determine the effects of a low-carbohydrate diet compared to a low-fat/high-carbohydrate diet on glucose control in patients who have Type 2 Diabetes.


Options:
A: Arm Label: Low-carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: low-carbohydrate diet | Arm Label: Low-fat diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: low-fat diet | Intervention Type: BEHAVIORAL; Name: low-carbohydrate diet; Assigned to Arm(s): Low-carbohydrate diet | Intervention Type: BEHAVIORAL; Name: low-fat diet; Assigned to Arm(s): Low-fat diet
B: Intervention Type: BEHAVIORAL; Name: low glycemic load diet; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: low fat diet; Assigned to Arm(s): N/A
C: Arm Label: 20% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 20% protein-diet | Arm Label: 27% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 27% protein-diet | Arm Label: 35% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 35% protein-diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 20% protein-diet; Assigned to Arm(s): 20% protein hypocaloric diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 27% protein-diet; Assigned to Arm(s): 27% protein hypocaloric diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 35% protein-diet; Assigned to Arm(s): 35% protein hypocaloric diet
D: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High and Low Carbohydrate Weight Loss Approaches to Type 2 Diabetes Mellitus (The Diabetes Dietary Study (DDS))
Brief Summary: The purpose of this study is to determine the effects of a low-carbohydrate diet compared to a low-fat/high-carbohydrate diet on glucose control in patients who have Type 2 Diabetes.


Options:
A: Arm Label: Low-Carbohydrate Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low-Carbohydrate Diet | Arm Label: Usual Diet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Low-Carbohydrate Diet; Assigned to Arm(s): Low-Carbohydrate Diet
B: Arm Label: CRHP Diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: CRHP Diet | Arm Label: CD Diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: CD Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: CRHP Diet; Assigned to Arm(s): CRHP Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: CD Diet; Assigned to Arm(s): CD Diet
C: Arm Label: Low-carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: low-carbohydrate diet | Arm Label: Low-fat diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: low-fat diet | Intervention Type: BEHAVIORAL; Name: low-carbohydrate diet; Assigned to Arm(s): Low-carbohydrate diet | Intervention Type: BEHAVIORAL; Name: low-fat diet; Assigned to Arm(s): Low-fat diet
D: Arm Label: Low-Carb High-Fat Breakfast; Type: EXPERIMENTAL; Interventions: Other: Low-Carb High-Fat breakfast | Arm Label: Low fat "Standard Care" Control Breakfast; Type: ACTIVE_COMPARATOR; Interventions: Other: Low fat "standard care" control breakfast | Intervention Type: OTHER; Name: Low-Carb High-Fat breakfast; Assigned to Arm(s): Low-Carb High-Fat Breakfast | Intervention Type: OTHER; Name: Low fat "standard care" control breakfast; Assigned to Arm(s): Low fat "Standard Care" Control Breakfast

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome
Brief Summary: 1. Metformin increases the pregnancy rate when added to the standard treatment of anovulatory polycystic ovary syndrome (PCOS).
2. Metformin in combination with clomiphene, is more effective than clomiphene alone or metformin alone improves fertility outcomes in women with PCOS of reasonably healthy body weight (BMI \</= 32).
3. Metformin improves fertility outcomes in women with BMI \> 32 with PCOS.


Options:
A: Intervention Type: DRUG; Name: metformin XR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): N/A
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
D: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome
Brief Summary: 1. Metformin increases the pregnancy rate when added to the standard treatment of anovulatory polycystic ovary syndrome (PCOS).
2. Metformin in combination with clomiphene, is more effective than clomiphene alone or metformin alone improves fertility outcomes in women with PCOS of reasonably healthy body weight (BMI \</= 32).
3. Metformin improves fertility outcomes in women with BMI \> 32 with PCOS.


Options:
A: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32
B: Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): N/A
C: Arm Label: Low Glycemic Index Diet Group; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index Diet Group | Arm Label: Conventional Diet Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Diet Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Glycemic Index Diet Group; Assigned to Arm(s): Low Glycemic Index Diet Group | Intervention Type: OTHER; Name: Conventional Diet Group; Assigned to Arm(s): Conventional Diet Group
D: Arm Label: liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: EXPERIMENTAL; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome
Brief Summary: 1. Metformin increases the pregnancy rate when added to the standard treatment of anovulatory polycystic ovary syndrome (PCOS).
2. Metformin in combination with clomiphene, is more effective than clomiphene alone or metformin alone improves fertility outcomes in women with PCOS of reasonably healthy body weight (BMI \</= 32).
3. Metformin improves fertility outcomes in women with BMI \> 32 with PCOS.


Options:
A: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo
B: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide
C: Intervention Type: DRUG; Name: metformin XR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): N/A
D: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stimulant and Risperidone in Children With Severe Physical Aggression
Brief Summary: This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate HCl, Drug: Risperidone, Behavioral: Parent Management Training (PMT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate HCl, Behavioral: Parent Management Training (PMT), Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate HCl; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Parent Management Training (PMT); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Divalproex Sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Mixed Amphetamine Salts; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family Counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Behavior Management Training with Parents; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stimulant and Risperidone in Children With Severe Physical Aggression
Brief Summary: This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).


Options:
A: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
B: Arm Label: 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 15 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsules; Assigned to Arm(s): 10 mg, 15 mg, 20 mg, 40 mg, Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate HCl, Drug: Risperidone, Behavioral: Parent Management Training (PMT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate HCl, Behavioral: Parent Management Training (PMT), Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate HCl; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Parent Management Training (PMT); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Endometrial Injury in the Non-Transfer Cycle Improve the IVF-ET Outcome in the Subsequent Cycle in Patients With Previous Failed IVF Cycles: A Randomized Control Trial
Brief Summary: Implantation of the human embryo is the limiting factor in the success of invitro-fertilization and embryo transfer(IVF-ET).We wanted to find out whether creating a local injury to the endometrium in the non-transfer cycle would improve the IVF-ET outcome in the subsequent cycle.We believe that the injury created causes release of substances which help in implantation.


Options:
A: Arm Label: Office hysteroscopy and endometrial snip; Type: EXPERIMENTAL; Interventions: Procedure: Office hysteroscopy and endometrial snip | Arm Label: Office hyteroscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Office hysteroscopy | Intervention Type: PROCEDURE; Name: Office hysteroscopy and endometrial snip; Assigned to Arm(s): Office hysteroscopy and endometrial snip | Intervention Type: PROCEDURE; Name: Office hysteroscopy; Assigned to Arm(s): Office hyteroscopy
B: Arm Label: Pipelle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Pipelle de Cornier | Arm Label: Explora group; Type: ACTIVE_COMPARATOR; Interventions: Device: Explora curette | Intervention Type: DEVICE; Name: Pipelle de Cornier; Assigned to Arm(s): Pipelle Group | Intervention Type: DEVICE; Name: Explora curette; Assigned to Arm(s): Explora group
C: Arm Label: Biopsy catheter; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): Biopsy catheter | Intervention Type: PROCEDURE; Name: Endometrial Biopsy; Assigned to Arm(s): Biopsy catheter
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: PIPELLE ENDOMETRIAL SAMPLING | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: PIPELLE ENDOMETRIAL SAMPLING; Assigned to Arm(s): 1

Answer: D